Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2024

Correspondence / Letter

Phase 3 randomized trial of peficitinib in Asian patients with RA

Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study.

The Lancet regional health. Western Pacific

Citation & Authors

Lancet Reg Health West Pac. 2024;42:100925.

Yue Yang; Jingyang Li; Ju Liu; Lin Liu; Yongfu Wang; Jiankang Hu; Zhijun Li; Jieruo Gu; Xiao Zhang; Zhengyu Xiao; Junjie Zheng; Zhanguo Li; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

385 Asian patients with RA who had an inadequate response or intolerance to methotrexate were randomized to peficitinib 100 mg, 150 mg, or placebo. At week 24 or early termination, ACR20 response rates were 56.6%, 56.3%, and 24.2%, respectively. Both doses were superior to placebo, but the higher dose showed no additional benefit. Herpes zoster-related disease occurred more frequently in the peficitinib groups and should be considered alongside efficacy.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗